<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01497379</url>
  </required_header>
  <id_info>
    <org_study_id>HKCTR-1198</org_study_id>
    <secondary_id>RI-MC-CT-2009</secondary_id>
    <nct_id>NCT01497379</nct_id>
  </id_info>
  <brief_title>Safety &amp; Efficacy of Subretinal Implants for Partial Restoration of Vision in Blind Patients</brief_title>
  <official_title>Safety &amp; Efficacy of Subretinal Implants for Partial Restoration of Vision in Blind Patients: A Prospective Mono- &amp; Multicenter Clinical Study Based on Randomized Intra-individual Implant Activation in Degenerative Retinal Disease Patients.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Retina Implant AG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Retina Implant AG</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients who are legally blind, caused by retinal degeneration of photoreceptor rods &amp; cones
      (e.g. Retinitis pigmentosa), receive a subretinal implant to restore vision partially.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2011</start_date>
  <completion_date type="Actual">January 2015</completion_date>
  <primary_completion_date type="Actual">January 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety</measure>
    <time_frame>1 year</time_frame>
    <description>treatment shows no permanent damage of function and structures that have been functional before surgery and no permanent damage to health and/or well being of patients</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Efficacy</measure>
    <time_frame>1 year</time_frame>
    <description>Activities of Daily Living &amp; Mobility are significantly improved with implant-ON versus OFF, as shown via tests:
Activities of Daily Living tasks or
Recognition tasks or
Mobility or
a combination of the above</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety</measure>
    <time_frame>1 year</time_frame>
    <description>Patient long term safety:
stability of implant function
stability of body structure &amp; function related to implant system</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy</measure>
    <time_frame>1 year</time_frame>
    <description>Visual Acuity / Light-perception and/or Object-recognition are significantly improved with implant-ON versus OFF as shown via:
FrACT or
BaLM or
Grating test (e.g. BaGA) and/or Quality of life
Quality of life (questionnaire) or
a combination of the above</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">2</enrollment>
  <condition>Retinal Degeneration</condition>
  <condition>Retinitis Pigmentosa</condition>
  <arm_group>
    <arm_group_label>intra-individual implant ON</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>intra-individual implant activation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>intra-individual implant OFF</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>intra-individual implant deactivation</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>surgical implantation of subretinal device</intervention_name>
    <description>surgical implantation of subretinal device</description>
    <arm_group_label>intra-individual implant ON</arm_group_label>
    <other_name>Retinal implant, subretinal implant</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>surgical implantation of subretinal device</intervention_name>
    <description>intra-individual implant OFF</description>
    <arm_group_label>intra-individual implant OFF</arm_group_label>
    <other_name>Retinal implant, subretinal implant</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Hereditary retinal degeneration of the outer retinal layers i.e. photoreceptor rods &amp;
             cones.

          -  Pseudophakia

          -  Angiography shows retinal vessels adequately perfused, despite pathological RP
             condition.

          -  Age between 18 and 78 years.

          -  Blindness (at least monocular) i.e. visual functions not appropriate for localization
             of objects, self sustained navigation and orientation (impaired light localization or
             worse).

          -  Ability to read normal print in earlier life, optically corrected without magnifying
             glass.

          -  Willing and able to give written informed consent in accordance to EN ISO 14155
             (section 6.7) and local legislation prior to participation in the study. Able to
             perform the study during the full time period of one year

        Exclusion Criteria:

          -  Period of appropriate visual functions &lt; 12 years / lifetime.

          -  Optical Coherence Tomography (OCT) shows significant retina edema &amp;/or scar tissue
             within target region for implant.

          -  Retina detected as too thin to expect required rest-functionality of inner retina as
             shown via Optical Coherence Tomography (OCT).

          -  Lack of inner-retinal function, as determined by Electrically Evoked Phosphenes (EEP).

          -  Heavy clumped pigmentation at posterior pole

          -  Any other ophthalmologic disease with relevant effect upon visual function (e.g.
             glaucoma, optic neuropathies, trauma, diabetic retinopathy, retinal detachment).

          -  Amblyopia reported earlier in life on eye to be implanted

          -  Systemic diseases that might imply considerable risks with regard to the surgical
             interventions and anaesthesia (e.g. cardiovascular/ pulmonary diseases, severe
             metabolic diseases).

          -  Neurological and/or psychiatric diseases (e.g. M. Parkinson, epilepsy, depression).

          -  Hyperthyroidism or hypersensitivity to iodine

          -  Women who are pregnant or nursing, or women of childbearing potential who are not
             willing to use a medically acceptable means of birth control for the duration of the
             study, or women unwilling to perform a pregnancy test before entering the study.

          -  Participation in another interventional clinical trial within the past 30 days.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>78 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Wong, Prof., MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chair Professor in Ophthalmology Eye Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ophthalmology Eye Institute, University of Hong Kong</name>
      <address>
        <city>Hong Kong</city>
        <state>Cyberport</state>
        <zip>100</zip>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Hong Kong</country>
  </location_countries>
  <link>
    <url>http://www.hkclinicaltrials.com/</url>
    <description>Hong Kong clinical trials registry</description>
  </link>
  <results_reference>
    <citation>Stingl K, Bartz-Schmidt KU, Besch D, Chee CK, Cottriall CL, Gekeler F, Groppe M, Jackson TL, MacLaren RE, Koitschev A, Kusnyerik A, Neffendorf J, Nemeth J, Naeem MA, Peters T, Ramsden JD, Sachs H, Simpson A, Singh MS, Wilhelm B, Wong D, Zrenner E. Subretinal Visual Implant Alpha IMS--Clinical trial interim report. Vision Res. 2015 Jun;111(Pt B):149-60. doi: 10.1016/j.visres.2015.03.001. Epub 2015 Mar 23.</citation>
    <PMID>25812924</PMID>
  </results_reference>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 15, 2011</study_first_submitted>
  <study_first_submitted_qc>December 19, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 22, 2011</study_first_posted>
  <last_update_submitted>March 28, 2017</last_update_submitted>
  <last_update_submitted_qc>March 28, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 29, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hereditary retinal</keyword>
  <keyword>degeneration outer</keyword>
  <keyword>retinal layers</keyword>
  <keyword>photoreceptor rods cones</keyword>
  <keyword>Retinitis pigmentosa</keyword>
  <keyword>blindness</keyword>
  <keyword>reading ability</keyword>
  <keyword>retina implant</keyword>
  <keyword>subretinal</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Retinitis</mesh_term>
    <mesh_term>Retinitis Pigmentosa</mesh_term>
    <mesh_term>Cone-Rod Dystrophies</mesh_term>
    <mesh_term>Retinal Degeneration</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

